<DOC>
	<DOC>NCT00676650</DOC>
	<brief_summary>This study will compare the safety and efficacy of sunitinib in combination with prednisone versus placebo and prednisone in patients that have metastatic castration-resistant prostate cancer that has progressed after treatment with a docetaxel-containing chemotherapy regimen. This is a second-line study.</brief_summary>
	<brief_title>Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Histologically or cytologically confirmed adenocarcinoma of the prostate. Progressive, metastatic castrationresistant prostate cancer after failure of docetaxel chemotherapy (resistant or intolerant). Progressive disease based on PSA progression, RECIST, or positive bone scan. ECOG 0 or 1. Prior treatment with sunitinib and/or more than 1 prior chemotherapy regimen in the metastatic disease setting. Chemotherapy within 3 weeks. Impending complications from bone metastases. Ongoing urinary obstruction. Cardiac dysfunction, QTc &gt;470 msec. CNS involvement.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Docetaxel-refractory mCRPC</keyword>
	<keyword>Second-line treatment with sunitinib and prednisone</keyword>
</DOC>